Hydab Capsule
Hydroxyurea (Hydroxycarbamide)
500mg
DABUR INDIA LTD.
| Pack size | |
|---|---|
| Dispensing mode | |
| Source | |
| Agent | |
| Retail Price | 24.13 NPR |
Indications
Hydab Capsule is used for:
Chronic myeloid leukaemia, Psoriasis, Myeloproliferative disorders, Sickle-cell disease, Essential thrombocythemia, AIDS
Adult Dose
Solid Tumors
Intermittent Therapy: 80 mg/kg PO q3day, OR
Continuous Therapy: 20-30 mg/kg PO qDay
Head & Neck Tumors
Concomitant therapy with irradiation
80 mg/kg PO q3days
Begin 7 days prior to initiation of irradiation
Chronic Myelocytic Leukemia, Resistant
Continuous Therapy: 20-30 mg/kg PO qDay
Sickle Cell Disease
Start: 15 mg/kg/day as single dose; monitor patient’s blood count every two weeks
Titrate by 5 mg/kg/day q12wk
Dose is not increased if blood counts are between acceptable range and toxic
Not to exceed 35 mg/kg/day
Discontinue therapy until hematologic recovery if blood counts are considered toxic; may resume treatment after reducing dose by 2.5 mg/kg/day from dose associated with hematological toxicity
Thrombocythemia, Essential
15 mg/kg PO qDay
Titrate to control platelets & maintain WBC count
Child Dose
Oral
Sickle-cell disease
Child: 1-18 yr: 10-20 mg/kg/day, increased by 5 mg/kg/day every 12 wk according to response and blood counts.
Renal Dose
Renal impairment: Dose reduction may be needed.
Administration
Contra Indications
Severe bone-marrow suppression, severe anaemia, WBC <3000/mm3 or platelet count <100,000/mm3. Pregnancy and lactation. Hypersensitivity.
Precautions
Regular monitoring of uric acid concentrations, blood counts, renal and hepatic function is recommended. Prior irradiation therapy. Elderly. Avoid use of live vaccines.
Lactation: excreted in breast milk, do not nurse
Pregnancy-Lactation
Interactions
Impairs immune response to vaccines; possible infection with live vaccines, zidovudine, zalcitabine. May alter action of oral anticoagulants and phenytoin.
Potentially Fatal: Fluorouracil may increase potential for neurotoxicity. Modulates metabolism and cytotoxicity of cytarabine. May precipitate didanosine- or stavudine-induced pancreatitis, hepatotoxicity or neuropathy.
Adverse Effects
Side effects of Hydroxyurea (Hydroxycarbamide) :
GI disturbances, Nausea, Vomiting, Constipation, Diarrhea, Hyperuricemia, Renal failure, Rash, Hyperpigmentation. Pulmonary oedema, dermatological reactions, headache, dizziness. Disorientation, drowsiness, hallucinations, convulsions, alopecia.
Potentially Fatal: Bone marrow suppression.
Mechanism of Action
Hydroxycarbamide causes inhibition of DNA synthesis during the S-phase of cell division by acting as a ribonucleotide reductase inhibitor resulting to cell death. It is S-phase specific.
Note
Hydab 500mg Capsule manufactured by DABUR INDIA LTD.. Its generic name is Hydroxyurea (Hydroxycarbamide). Hydab is availble in Nepal.
Farmaco Nepal drug index information on Hydab Capsule is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.